The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Both men and women with psoriasis are equally at risk for developing psoriatic arthritis (PsA)—a chronic inflammatory ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Synovitis is significantly more likely among patients with psoriasis, and it is more likely among those with PsA than PsO.

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...

A lthough most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the ...